Premium
In vitro response of osteoarthritic chondrocytes and fibroblast‐like synoviocytes to a 500–730 kDa hyaluronan amide derivative
Author(s) -
Brun Paola,
Zavan Barbara,
Vindigni Vincenzo,
Schiavinato Antonella,
Pozzuoli Assunta,
Iacobellis Claudio,
Abatangelo Giovanni
Publication year - 2012
Publication title -
journal of biomedical materials research part b: applied biomaterials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.665
H-Index - 108
eISSN - 1552-4981
pISSN - 1552-4973
DOI - 10.1002/jbm.b.32771
Subject(s) - cd44 , chemistry , fibroblast , in vitro , tumor necrosis factor alpha , osteoarthritis , inflammation , microbiology and biotechnology , cancer research , pharmacology , immunology , medicine , biochemistry , pathology , biology , alternative medicine
The aim of this study was to compare the effects of native hyaluronan (HA) with that of its hexadecylamide derivative (HYADD) on proliferation of fibroblast‐like synoviocytes (FLS) and chondrocytes. The production of inflammatory and anti‐inflammatory cytokines was also analyzed in FLS cultures. The proliferation of osteoarthritis (OA) chondrocytes was enhanced when cells were treated with 0.5–1.5 mg mL −1 of HA or HYADD®4‐G. This effect was completely suppressed by the anti‐CD44 antibody. At 0.5 to 1 mg mL −1 , HA and HYADD®4‐G did not influence the proliferation of normal or pathological FLS; however, at the higher concentration (1.5 mg mL −1 ), HYADD®4‐G did significantly inhibit cell proliferation. As to effects on inflammation, a significant increase in the expression of the IL‐10 gene was observed when FLS were pretreated with tumor necrosis factor alpha and then cultured in the presence of 0.5 mg mL −1 HYADD® 4‐G or HA. The effects of HA derivatives on FLS proliferation and production of anti‐inflammatory cytokines indicate that they may be of therapeutic benefit in OA. The longer residence time in the joint cavity, the increased viscoelasticity, and the anti‐inflammatory potential of HYADD®4‐G make it a better candidate than native HA for OA therapy. © 2012 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 2012.